相关实验视频

Updated: May 15, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

使用大数据发现前列腺癌患者的药物基因相互作用

Huiyi Yang¹, Joseph Finkelstein¹

¹University of Utah.

Studies in health technology and informatics

|April 9, 2025

概括

药物基因组学 (PGx) 可以优化老年人的药物. 这项研究发现,20%的前列腺癌患者改变了CYP2D6酶功能,影响了药物代谢,并突出了PGx.

科学领域:

遗传学和基因组学遗传学和基因组学
药理学药理学是指药理学的学科.
在瘤学瘤学.

背景情况:

药物基因组学 (PGx) 提供个性化药物优化,对于多药的老年人来说至关重要.
酶CYP2D6的变体显著影响药物代谢,但它们在前列腺癌 (PPC) 患者中的患病率未得到充分研究.
PPC患者主要是老年人,因此他们容易受到多药和药物基因相互作用的影响.

研究的目的:

在一大批前列腺癌患者中调查CYP2D6基因变异的患病率及其功能影响 (表型).
评估与该患者群体中CYP2D6代谢相关的潜在药物基因相互作用的程度.
探索CYP2D6药物基因组学对前列腺癌护理中的药物管理的临床影响.

主要方法:

来自"我们所有人"研究计划的3000多名前列腺癌患者中CYP2D6基因型和表型的分析.
基因数据与医疗处方记录的相关性,以确定药物基因相互作用.
评估可操作的表型和先前接触CYP2D6代谢的药物.

主要成果:

大约20%的前列腺癌患者被确定为非正常的CYP2D6代谢器 (差,中等或超快).
67%的患者被处方至少一种主要或部分由CYP2D6代谢的药物.
13%的患者表现出可操作的药物基因组表型,此前曾接触过相关药物.

结论:

在前列腺癌患者中存在CYP2D6代谢变化的显著流行.
由于CYP2D6介导的药物基因相互作用,很大一部分患者面临低于最佳药物治疗的风险.
实施CYP2D6的药物基因组指南有可能改善药物处方和前列腺癌护理中的患者结果.

关键词:

大数据的大数据大数据在CYP2D6中.药物遗传学药物遗传学前列腺癌是前列腺癌.

更多相关视频

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

相关概念视频

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...